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Introduction: To the best of our knowledge, the presence of a trilobed nonfunctional giant
pituitary adenoma has never been described before in the literature. These tumors present
unique diagnostic and therapeutic challenges. Tumors of this etiology can be managed
with pharmacologic treatment or aggressive surgical intervention. The following case
illustrates an unique visual presentation of a giant pituitary adenoma.
Case Presentation:We report the case of a 40-year-old Hispanicmanwho presentedwith new
onset seizures. Radiological imaging showed the presence of a trilobed giant pituitary ad-
enoma extending anterior into the frontal lobe, posterior to the hypothalamus, and inferior.
The patient underwent a right pteronial craniotomy to remove majority of his tumor.
Conclusions: The large size of the tumor should be considered in the differential diagnosis of
various other conditions leading to a pituitary region mass such as a craniopharyngioma,
pituitary metastasis, pituitary carcinoma, and a meningioma. Careful planning and
outlining of therapeutic interventions are needed to rectify this abnormality. Those
patients who meet the qualifications of a combined transsphenoidal and transcranial
procedure should opt for this method of tumor resection.
© 2016 the Authors. Published by Elsevier Inc. under copyright license from the University
of Washington. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
The pituitary gland belongs to a group of endocrine organs,
which is responsible for the synthesis and/or release of hor-
mones, which act on various organs through the body.lared that no competing
m (R.M. Vakharia).
Elsevier Inc. under copy
se (http://creativecommoNeoplastic transformation of this organ can lead to the over-
production of certain hormones, which is amenable by
various pharmaceutical agents or by surgical intervention,
especially for those when conservative treatment has failed.
Pituitary growths with normal hormonal levels are defined asinterests exist.
right license from the University of Washington. This is an open
ns.org/licenses/by-nc-nd/4.0/).
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adenomas are the most common types of pituitary adenomas
[1]. Additional methods of grouping these tumors include
classifying them by size. Tumors smaller than 1 cm are
termed microadenomas, whereas those larger than 1 cm are
defined as a macroadenoma.
Additional increases in size greater than 4 cm are classi-
fied as a “giant adenoma” [2]. Occasionally, these giant
tumors are often very aggressive and can follow a malignant
course [3]. The invasive nature of giant adenomas is
anatomically classified using the modified Hardy system. The
system is divided looking at the extrasellar extension and
intersellar invasion and/or spread of the tumor. The extra-
sellar extension is further subclassified as either having a
suprasellar extension or a parasellar extension. Each of these
are further subdivided depending on their extent. Intersellar
invasion and/or spread is further subclassified as either floor
of sella intact, sphenoid extension, or having distant spread.
These groups are even further subclassified. Hardy’s classi-
fication of the suprasellar extension of pituitary adenomas
uses the relationship of the superior capsule of the tumor
with the third ventricle and takes into account asymmetric
extension in the coronal plane [4].
Here, we discuss a giant trilobed pituitary adenoma with
bilateral suprasellar extensions anterior and posterior, with
an intersellar invasion and/or spread. We also discuss the
pathogenesis of this lesion.Case presentation
A 40-year-old Hispanic man of Mexican descent, with no
relevant medical history, was brought into the emergency
department with his wife for a new onset seizure. The patient
has no family history or prior seizure episodes.
When returning home from work, he had a seizure
episode in the shower witnessed by his wife, which at that
point she called 911. En route to the hospital, the patient had
a second episode and was admitted. His wife states that she
had noticed a change in the husband’s personality these past
several months stating it to be a “child-like behavior.” Elec-
trolyte imbalance and the presence of recreational drugs
were ruled out as a possible cause of the seizure episodes.
Vital signs were within normal limits at the time of admis-
sion. Magnetic resonance imaging (MRI) showed the presence
of a trilobed pituitary tumor measuring 42 mm craniocaudal,
50 mm anteroposterior, 28 mm transverse, and a height of
46 mm. (Figs 1A-D). The left anterior cerebral artery is dis-
placed to the left side by the mass. The right anterior cerebral
artery is also displaced to the right by the mass (Fig. 1E). With
the help of the modified Hardy classification system, the
tumor fits the category of a stage D (intracranial/intradural)
and grade IV (diffuse perforation of sellar floor). The patient
was transferred to the intensive care unit for further obser-
vation. The physical examination performed by general sur-
gery, demonstrated a loss of peripheral vision. The patient
was later transferred under the service of neurosurgery.
Under the service of neurosurgery, hormone levels were ob-
tained showing to be within normal reference range. Formalvisual testing confirmed the presence of bitemporal
hemianopsia.
The patient underwent a right pteronial craniotomy.
Posteromedial to the optic nerve and carotid artery was an
area discrete from the surrounding structures. The encapsu-
latedmass correlatedwith the position of the tumor as using a
frameless stereotactic device. The capsule was coagulated
using bipolar cautery and incised with a #11 blade. Pink
colored, moderately granular soft friable tumor was encoun-
tered within this capsule. As the tumor was soft and “suck-
able,” internal debulking of the suprasellar region of the tumor
was begun using a combination of suction and bipolar cau-
tery. In this matter, the ipsilateral optic nerve and the carotid
artery were decompressed enough for the arachnoid of the
opticocarotid cistern to be identified. Once this was identified,
a #11 bladewas used to carefully incase the arachnoid over the
optic-carotid system with egress of more cerebrospinal fluid,
which allowed for further brain retraction. In this manner, the
entire frontal lobe portion of the tumor and its attached
capsule was able to be resected in their entirety, and these
were sent for pathology.
Further debulking of the posterior lobe of the tumor was
carefully accomplished using a combination of suction and
bipolar cautery technique. The posterior portion of the tumor
was adjacent to the hypothalamus and the third ventricle, and
this was carefully debulked in the same manner as the ante-
rior lobe. Majority of the tumor was resected and sent for bi-
opsy. Tumor capsule was again able to be identified and was
able to be grasped with pituitary forceps, and in this manner,
the posterior lobe of the tumor was able to be delivered from
its position anterior to the third ventricle into the operative
field where it could be further debulked and resected using
intraoperative suction.
Once the posterior portion of the tumor was debulked
further partial debulking of the intrasellar component was
completed. Some residual intrasellar component was left
intact as not to injure native functional pituitary tissue.
The final diagnosis was a pituitary adenoma. Microscopy
revealed in general a homogenous cell population with min-
imal cytologic atypia, prominent vascular pattern imparting a
perivascular pseudorosette feature without a mixture of other
pituitary normocellular elements, and rare mitosis. Immu-
nohistochemical stains for cytokeratin AE1/AE3 is strongly
positive with focal to weak reaction with epithelial membrane
antigen. Adrenocorticotrophic hormone is positive only on the
residual rim of pituitary gland, but the rest of the tumor is
negative. Prolactin (PRL), luteinizing hormone, follicular
stimulating hormone, and growth hormone are positive in
varying degrees. PRL appeared to be predominant hormone.
Thyroid stimulating hormone is negative. Glial fibrillary acid
protein and CD99 are negative. Ki-67 demonstrates less than
5% proliferation index. S-100 is focally positive. The patient
was kept in the Critical Care Unit for postoperative
observation.
Postoperative day 2, MRI revealed the trilobed mass lesion
had been removed. The posterosuperior lobe that was com-
pressing the cerebral peduncles had been resected. The
anterosuperiormass,whichwas compressing the frontal lobe,
had also been resected. The mass consisting of the pituitary
gland, and extending into, and occupying the suprasellar
Fig. 1 e (A) T2 sagittal MRI showing the trilobed giant pituitary adenomawith anterior and posterior suprasellar extensions.
(B) T2 sagittal MRI showing the craniocaudal dimensions of the tumor measuring at 41.95 mm. (C) T2 sagittal MRI showing
the anteroposterior dimensions of the tumor measuring at 50.37 mm. (D) T2 axial MRI showing a transverse measurement
of 28.11. The bilobed appearance can be appreciated by this view. (E) Transverse image of the tumor showing the masses
displacing both the left and right anterior cerebral arteries (arrows).
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However, the MRI revealed the presence of enhancing tissue
within the expanded sellar, like a combination of the pituitary
gland, tumor tissue, and edema-blood (Fig. 2). In addition to
these findings, acute subdural bleeding is appreciated in the
right anterior lateral subdural space (Fig. 3). Postoperative day
9, a noncontrast computerized tomography was done
revealing the presence of acute blood in the subdural space in
the anterior right lateral subdural space. The maximal thick-
ness of the blood in the area is 1 cm (Fig. 4). A repeat non-
contrast computerized tomography done on postoperative
day 23 revealed less fluid in the right frontal postoperative
subdural space with a more chronic water attenuation
appearance to the remaining fluid. New bleeding had not
developed, and there were no signs of a mass effect. The brain
appeared normal elsewhere (Fig. 5).
Postoperative day 6, endocrinology was consulted due to
the patient having panhypopituitarism. Levels of cortisol,
free T3, free T4, thyroid stimulating hormone baseline, and
insulin-like growth factor or growth hormone were dimin-
ished. Sodium levels were elevated. To rectify these hor-
monal imbalances, the patient was started on synthroid 125mcg, hydrocortisone 20 mg every morning and 20 mg in the
afternoon. Intranasal desmopressin acetate was given to
control the sodium levels. Careful observation for the next
several days led to laboratory values returning to within
normal reference range. The patient was subsequently dis-
charged 16 days after the initial admission.Discussion
Giant pituitary adenomas are those tumors, which are
greater than 4 cm in the maximum measured dimensions.
These tumors can be classified depending on the extent of
spread by classifying them into various grades. Grade I are
those, which remain within the confines of the sella dura and
inferior to the diaphragm sellae, but no invasion into the
cavernous sinus. Those adenomas which spread to the
medial wall and followed with invasion into the cavernous
sinus are grade II.
Elevation of the dura of the superior wall of the cavernous
sinus and spread into various brain compartments is catego-
rized as grade III. At last, the adenomas, which have a
Fig. 4 e Noncontrast CT images showing the presence of an
acute subdural hematoma.
Fig. 2 e T2 sagittal MRI showing the postoperative changes
of the patient.
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as grade IV [5].
Treatment options for these giant adenomas vary from
either medical management or with surgical management.
The former is restricted to adenomas which are PRL secretors.Fig. 3 e Axial MRI showing the presence of the subdural
hematoma located in the right frontal aspect.Dopamine agonists such as bromocriptine can be used to
manage these patients. However, a recent study has shown
that bromocriptine had been an effective therapeutic agent for
a giant nonfunctional pituitary adenoma, based on the
absence of enlargement, after an early bromocriptine treat-
ment withdrawal. The study by Barquiel et al. [6] had
bromocriptine levels that were progressively increased from
1.25 to 3.75 mg orally daily. Bromocriptine dose for a pro-
lactinoma ranges 2.5-15.0 mg per day. Serum PRL levels
normalized within 2 months of initiation of bromocriptine.
The mass showed a maximum diameter of 1.3 cm after 6
months of treatment. Before initiation, the maximum linear
diameter was 2.3 cm. After, the adenoma had decreased to a
maximum linear diameter of 0.9 cm. In addition to these
findings, signs of an extrasellar invasion had also dis-
appeared. For those patients where pharmacologic interven-
tion does not have any affect on the tumor, surgical
intervention can be done.
Surgical intervention of giant pituitary adenomas with
suprasellar extensions can present a daunting task. These
tumors with suprasellar extension and visual compromise
were indications for a transfrontal approach for the past 2
decades [7]. Traditionally, a transsphenoidal approach was
the surgical method of choice for pituitary tumors [8]. Zhang
et al. [9] in 1999 found that the transsphenoidal approach is
safe and advantageous in that it allows for rapid and adequate
decompression of the optic nerves and chiasm, and the inci-
dence of side effects was lower compared with the trans-
frontal approach. However, one of the disadvantages found
with the transsphenoidal procedure is the lack of direct
visualization of the optic nerves and their blood supply [10]. In
Fig. 5 e Noncontrast CT showing no acute subdural
bleeding present.
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extrasellar extension that have a favorable configuration.
Tumors where the diaphragm sellae are compromised around
the pituitary stalk can extend and expand into the suprasellar
regiondmaking the transsphenoidal approach difficult. At
last, a fibrous consistency of the tumor is another limitation
for the transsphenoidal approach [10].
For many, the transcranial approach continues to play a
role in the management of pituitary adenomas that have an
irregular shape or eccentric extensions that could not be
reached through the transsphenoidal route [7]. Compared
with the transsphenoidal procedure, patients having under-
gone a transcranial procedure showed greater visual
improvement; however, the postoperative pituitary dysfunc-
tion offsets the visual improvement. In addition, limited
visualization of the intrasellar area and amount of brain
retraction are 2 additional disadvantages to this procedure [8].
The anterior and posterior suprasellar extension of our
patient is due to the diaphragm sellae becoming compro-
mised around the pituitary stalk. Neither transsphenoidal
nor a transcranial route alone would be likely to completely
resect the sellar and suprasellar components of the tumor.
For these reasons, a combined approach would be effective.
D’Ambrosio et al. [11] found the collaboration of a trans-
cranial and transsphenoidal approach increased visualiza-
tion of critical neurovascular structures. The combined
approach was also found advantageous for patients with
bicompartmental (types A-D stage) lesions and any of the risk
factors for visual loss with transsphenoidal approach
(ie, giant pituitary adenomas, previous visual impairment,“bottle-neck” or dumbbell-shaped tumors [type B in modified
Hardy classification], previous surgery, and radiation
therapy) [10].
A recent study by Alleyne et al., 9 of the 10 patientswith the
combined procedure all had visual improvement within
1 month after surgery. In 5 patients, the resolution was com-
plete at 6 months after the surgery, whereas in the other
4 patients, the resolutionwas partial. None of the patients had
worsening of vision. However, new oculomotor nerve palsy
occurred in 3 patients. The palsy had resolved after 4 months
follow-up in 1 patient and at 12months in the other 2 patients.
Complications, which were permanent in this study, included
diabetes insipidus, hypothyroidism, and an infarct of the left
head of the caudate nucleus.Conclusions
In summary, we reported the findings of a trilobed giant pi-
tuitary adenoma in a 40-year-oldman, which was removed by
means a right pteronial craniotomy procedure. Various sur-
gical interventions have evolved to excise pituitary tumors,
when pharmacologic intervention has failed or for those
candidates where pharmacologic intervention would not
help. Evolution of these procedures has aimed at minimizing
intraoperative and postoperative complications in patients,
all while maintaining safe and efficacious measures. A
transfrontal procedurewas initially used, which progressed to
the use of a transsphenoidal procedure, due to minimization
of side effects. The transcranial approach aimed at resection
of tumors, which were out of the scope for transsphenoidal
procedure. In addition, the transcranial method provided an
increase in visualization of critical neurovascular structures,
which the transsphenoidal method failed to do. Combining
the transsphenoidal and transcranial methods, it has shown
optimum results in many patients by having near total or
complete resection of the tumor, partial or complete visual
recovery, and no permanent complications.r e f e r e n c e s
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